Mizuho analyst Graig Suvannavejh downgraded Adaptimmune Therapeutics plc (NASDAQ: ADAP) from Outperform to Neutral with a price target of $0.50 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE